Crossmark

Patients with chronic hepatitis B exhibiting significant inflammation and fibrosis should pay particular attention to the status of hepatic steatosis during antiviral therapy

Crossref DOI link: https://doi.org/10.1186/s12985-025-02703-z

Published Online: 2025-05-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yang, Bingqing

Yang, Tianyuan

Hou, Chenxue

Li, Yue

Wang, Qi https://orcid.org/0000-0002-0269-1568
License Information

Text and Data Mining valid from 2025-05-27

Version of Record valid from 2025-05-27
More Information

Article History

Received: 3 October 2024

Accepted: 11 March 2025

First Online: 27 May 2025

Declarations

:

: This study was conducted in accordance with the ethical standards set forth in the Helsinki Declaration and its subsequent amendments and was approved by the Institutional Review Board of Beijing Ditan Hospital, Capital Medical University (NO.DTEC-KY2021-046-04). This is a retrospective study involving no diagnostic or therapeutic interventions, and the data were anonymized. Therefore, the research centre’s ethics committee waived the requirement for patient informed consent.

: Not applicable.

: The authors declare no competing interests.

: During the preparation of this work the author(s) used ChatGPT 4.0 in order to improve readability and language. After using this tool, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

Document is current

Any future updates will be listed below